TLT
vs
S
S&P TSX Composite Index (Canada)
TLT
Over the past 12 months, TLT has underperformed S&P TSX Composite Index (Canada), delivering a return of +13% compared to the S&P TSX Composite Index (Canada)'s +36% growth.
Stocks Performance
TLT vs S&P TSX Composite Index (Canada)
Performance Gap
TLT vs S&P TSX Composite Index (Canada)
Performance By Year
TLT vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Theralase Technologies Inc
Glance View
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
